WO2013108263A1 - Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality - Google Patents

Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality Download PDF

Info

Publication number
WO2013108263A1
WO2013108263A1 PCT/IN2012/000045 IN2012000045W WO2013108263A1 WO 2013108263 A1 WO2013108263 A1 WO 2013108263A1 IN 2012000045 W IN2012000045 W IN 2012000045W WO 2013108263 A1 WO2013108263 A1 WO 2013108263A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucosamine
capsule
bones
taurine
reduce inflammation
Prior art date
Application number
PCT/IN2012/000045
Other languages
French (fr)
Inventor
Kamlesh Rajnikant Zota
Sanjay Agrawal
Ketan Chandulal Zota
Manukant Chandulal Zota
Himanshu Muktilal Zota
Original Assignee
Zota Health Care Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zota Health Care Ltd filed Critical Zota Health Care Ltd
Priority to PCT/IN2012/000045 priority Critical patent/WO2013108263A1/en
Publication of WO2013108263A1 publication Critical patent/WO2013108263A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention is based on an active ingredient composed of Glucosamine, MSM (Methyl Suphonil Methane), Taurine and Racemethionin, for the treatment of arthritis.
  • the invention is also effective in alleviating all kinds of joints pain and improving the quality of bone cartilage.
  • Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided.
  • the present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms.
  • the low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.
  • compositions comprising lysine, proline, arginine, vitamin C, magnesium, green tea extract, N-acetylcysteine, selenium, copper, manganese and one pharmaceutical acceptable component se l ected from the group consisting of a carrier, a diluent, and an excipient, wherein the pharmaceutical composition without the acceptable component contains 7-9 wt % magnesium, 20-30 wt % ascorbic acid and 11-25 wt % green tea extract
  • a method of treting cardio-vascular diseases using the pharmaceutical compositions are also disclosed, more preferably for the treatment of post-menopausal women
  • the present invention provides pharmaceutical compositions for alleviating pathological conditions in a post-menopausal woman, comprising lysine, proline, arginine, vitamin C, magnesium, green tea extract, N-acetyl-cysteine, selenium, copper, manganese and one pharmaceutical acceptable component selected from the group consisting of a carrier, a diluents, and an excipient, wherein the pharmaceutical composition without the acceptable component contains 7-9 wt % magnesium, 20-30 wt % ascorbic acid and 11-25 wt % green tea extract.
  • a method of treatment using the pharmaceutical compositions is also disclosed.
  • the present invention relates to a composition to enhance joint function, reduce inflammation and homocysteine levels, and repair cartilage.
  • the present invention relates to a nutritional supplement comprising a glucosamine-containing constituent, a chondroitin-containing constituent, methylsulfonylmethane, and at least one sulfur-containing amino acid.
  • a preferred sulfur- containing amino acid is taurine.
  • the nutritional supplement can also include folic acid, vitamins B6, B12, C.
  • the nutritional supplement can also include chromium and lipoic acid to improve insulin receptor sensitivity.
  • a composition suitable for the prevention and/or treatment of disorders due to abnormal lipid metabolism, such as hypercholesterolaemia, atherosclerosis, hyperlipidaemia and obesity, and which can therefore take the form of a dietary supplement or of an actual medicine, comprising as characterising active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, and (b) chitosan or its derivatives and congeners
  • a palatable viscous carrier for delivery of a variety of ingestible substances including dietary supplements, therapeutic agents, vitamins, and other probiotic agents.
  • the present invention protects components from contact with atmospheric oxygen and water that may degrade their quality.
  • the present invention also provides a natural oil coating to protect the ingestible substances from degradation by stomach acids.
  • the vehicle, herein described is easily dispensed using inexpensive, commonly available packaging such as collapsible tubes, two compartment aerosols, and pump dispensers.
  • the vehicle of the present invention is an anhydrous, hydrophobic, nontoxic vegetable oil base that can be made using commonly used manufacturing equipment.
  • the invention is directed primarily to veterinary applications, but also has applications in any industry involving the delivery of nutritional supplements and probiotic agents to living creatures.
  • the present invention relates generally to functional sweetener compositions comprising non-caloric or low-caloric natural and/or synthetic high-potency sweeteners and methods for making and using them.
  • the present invention relates to different functional sweetener compositions comprising at least one non-caloric or low- caloric natural and or synthetic high potency sweetener, at least one sweet taste improving composition, and at least one functional ingredient, such as glucosamine.
  • the present invention also relates to functional sweetener compositions and methods that can improve the tastes of non-caloric or low-caloric high- potency sweeteners by imparting a more sugar-like taste or characteristic.
  • the functional sweetener compositions and methods provide a more sugar-like temporal profile, including sweetness onset and sweetness linger, and/or a more sugar-like flavor profile.
  • composition which acts to protect, maintain and repair connective tissue in mammals.
  • the composition includes glucosamine, chondroitin sulfate and sulfur in an effervescent base as its major elements.
  • the effervescent base includes one or more acids and one or more bases and may also include a starch, a flavoring agent and a coloring agent.
  • the composition can be formed into a tablet or can be granular. The tablet or granular mixture is dissolved in a neutral pH liquid such as water for consumption purposes
  • compositions of and methods for producing timed or retarded release formulations that contain glucosamine sulfate, beta-(l,4)-2-amino-2-deoxy-D-glucose, and chondroitin, (C14 H19 N 014 S Na2)n; N-acetylchondrosamine (2-acetamide-2-deoxi-D-galactopiranose) and D-gluoronic acid copolymer and/or their dietary and nutraceutically acceptable salts of the same and/or hydrates of the active substance that provide a timed release formulation of the active substance.
  • a drug delivery system useful in treating individuals having maladies requiring topical, subcutaneous and intra-lesional administration of one or more drugs for a prolonged period of time A method for treating individuals with noduloulcerative carcinomas using the present invention drug delivery system and intra-lesional administration of interferon to the individual in a controlled, sustained release manner such that long-term therapeutic levels of interferon are provided to the individual.
  • a method of treating an individual having certain skin infections using the present invention drug delivery system including topical and/or subcutaneous administration of one or more drugs to the individual in a controlled, sustained release manner such that long-term therapeutic levels of the drug(s) are provided to the individual.
  • the present invention relates generally to anti-diabetic compositions comprising non-caloric or low-caloric high-potency sweeteners and methods for making and using mem.
  • the present invention relates to different anti-diabetic compositions comprising at least one non-caloric or low- caloric natural and/or synthetic high-potency sweetener, at least one sweet taste improving composition, and an anti-diabetic substance.
  • the present invention also relates to antidiabetic compositions and methods that can improve the tastes of non-caloric or low-caloric natural and/or synthetic, high-potency sweeteners by imparting a more sugar-like taste or characteristic.
  • the anti-diabetic compositions and methods provide a more sugar-like temporal profile, including sweetness onset and sweetness linger, and or a more sugar-like flavor profile.
  • a pain relief composition comprising an effective amount of a nerve inhibiting component, including capsaicin, a capsaicinoid or a capsaicin analogue, which numbs or inhibits the nerve endings that signal pain, in combination with at least one of the following: an effective amount of an inflammation control component which is designed to reduce immediate pain and discourage future pain in the joints and muscles; an effective amount of a cooling component; an effective amount of a heat minimizing or blocking component; an effective amount of a circulation increasing component which effectuates better penetration of the actives to the skin and nerves; and an effective amount of a soothing and anti-inflammatory complex for the joints and/or muscles comprising Glucosamine sulfate or HC1, Zingiber officiniale (Ginger Root) extract, Methyl sulfonylmethane (MSM), Polygonum cuspidatum (Mexican bamboo) extract, Aloe barbadensis leaf
  • a nerve inhibiting component including capsaicin, a capsa
  • This invention provides methods and formulations for treating an inflammatory disease or reducing an inflammatory reaction comprising administering a fortified formulation comprising stabilized rice bran derivative and a fortification agent.
  • Preferred rice bran derivatives are rice bran oil and the solubilized fraction of rice bran.
  • Preferred fortification agents are glucosamine derivative, methylsulfonylmethane, yucca concentrate, and grape seed extract. 2 000045
  • compositions and methods of administration are designed to effectively elevate and sustain blood levels of said compounds in turn enhancing the body's natural chondroprotective mechanisms while providing an efficient delivery mechanism which optimizes cellular uptake of glucosamine and chondroitin.
  • This process of forming specified synergistic relationships between vital metabolic precursors increases the body's production of proteoglycans, chondrocytes, hyalauron glycosaminoglycans and collagen, facilitating the repair and regeneration of articular cartilage and symptomatic relief from pain and inflammation associated with articular degeneration.
  • the object of the present invention is to introduce the use of an effective ingredient which is used in the treatment of arthritis.
  • Existing treatments has allergic effects and are costly.
  • This invention provides the novel combination of active ingredients which are Glucosamine, MSM (Methyl Suphonil Methane ), Taurine and Racemethionin.
  • the present invention provides novel and cost effective medicament of the active ingredients which are Glucosamine, MSM (Methyl Suphonil Methane ), Taurine and Racemethionin. DETAILED DESCRIPTION OF THE INVENTION
  • the present invention discloses novel, safe and economical composition for the joints pain treatments which comprises of the combination of four active ingredients like Glucosamine, MSM (Methyl Suphonil Methane), Taurine and Racemethionin.
  • the present invention is used for the treatment of arthritis, joints pain and improves cartilage quality also.
  • This invention comprises of following effective ingredients.
  • Glucosamine- Glucosamine is found in high concentrations in the joints. It has been theorized that glucosamine stimulates the formation of cartilage that is essential for joint repair. It has a beneficial effect on inflammation, mechanical arthritis, and immunological-reactive arthritis. It is natural. Glucosamine builds and maintains cartilage, tendons and other connective tissues in the body by acting as a building block for these materials and inhibiting enzymes that destroy cartilage. Glucosamine works by preventing the cartilage destruction, joint pain, swelling and loss of flexibility in a natural way and without the harmful side effects. It's the most popular arthritis nutrients, it's naturally occurring compounds that can aid in joint health and repair.The concentration of Glucosamine is 500mg/ capsule.
  • Methyl sulfonyl methane or MSM is a naturally occurring sulfur containing molecule found in fruits, vegetables, seafood and meat
  • MSM has anti-inflammatory effects. MSM significantly reduce pain and improve physical functioning, without major adverse events. Enhances permeability of cell membranes and reduces inflammation.
  • MSM aids in detoxifying metals by contributing sulfur to methionine and cysteine as well as peptides and proteins and is eventually incorporated into connective tissue. It's a naturally occurring sulfur compound that acts as an anti-inflammatory; MSM can reduce swelling much like other arthritis medications.
  • Methyl sulfonyl methane The concentration of Methyl sulfonyl methane is 25 mg /capsule.
  • Taurine tends to be well absorbed and tissue levels can go up rapidly after oral administration. Most of the supplemental uses of taurine is related to cardiovascular or muscle conditions. It does provide energy. The concentration of Taurine is 500 mg capsule.
  • L-Methionine has antioxidant properties.
  • Methionine is one of the three amino acids needed by the body to manufacture Creation, an amino acid essential for energy production and muscle building.
  • the concentration of racemethionin is 100 mg/capsule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention is based on an exclusive pharmaceutical formulation to reduce inflammation bones and joint friction with improve cartilage quality, comprising Glucosamine, MSM (Methyl Suphonil Methane), Taurine and RacemetMonin. The concentration of following ingredients are Glucosamine 500 mg/capsule, Methyl sulfonyl methane 25 mg/capsule, Taurine 500 mg/capsule and racemethionin 100 mg/capsule.

Description

PHARMACEUTICAL FORMULATION TO REDUCE INFLAMMATION OF BONES AND JOINT FRICTION WITH IMPROVED CARTILAGE QUALITY
FIELD OF INVENTION
The present invention is based on an active ingredient composed of Glucosamine, MSM (Methyl Suphonil Methane), Taurine and Racemethionin, for the treatment of arthritis. The invention is also effective in alleviating all kinds of joints pain and improving the quality of bone cartilage.
PRIOR ART
In the existing system as given in Patent application number: 20090258947 wherein Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.
In the existing system as given in United States Patent Application 20070166400 whereinThe present invention provides pharmaceutical compositions comprising lysine, proline, arginine, vitamin C, magnesium, green tea extract, N-acetylcysteine, selenium, copper, manganese and one pharmaceutical acceptable component selected from the group consisting of a carrier, a diluent, and an excipient, wherein the pharmaceutical composition without the acceptable component contains 7-9 wt % magnesium, 20-30 wt % ascorbic acid and 11-25 wt % green tea extract A method of treting cardio-vascular diseases using the pharmaceutical compositions are also disclosed, more preferably for the treatment of post-menopausal women
In the existing system as given in United States Patent Application 20050053674 wherein The present invention provides pharmaceutical compositions for alleviating pathological conditions in a post-menopausal woman, comprising lysine, proline, arginine, vitamin C, magnesium, green tea extract, N-acetyl-cysteine, selenium, copper, manganese and one pharmaceutical acceptable component selected from the group consisting of a carrier, a diluents, and an excipient, wherein the pharmaceutical composition without the acceptable component contains 7-9 wt % magnesium, 20-30 wt % ascorbic acid and 11-25 wt % green tea extract. A method of treatment using the pharmaceutical compositions is also disclosed.
In the existing system as given in (WO/2005/G41999) wherein the present invention relates to a composition to enhance joint function, reduce inflammation and homocysteine levels, and repair cartilage. The present invention relates to a nutritional supplement comprising a glucosamine-containing constituent, a chondroitin-containing constituent, methylsulfonylmethane, and at least one sulfur-containing amino acid. A preferred sulfur- containing amino acid is taurine. The nutritional supplement can also include folic acid, vitamins B6, B12, C. The nutritional supplement can also include chromium and lipoic acid to improve insulin receptor sensitivity.
In the existing system as given in United States Patent 6780851 wherein A composition is disclosed suitable for the prevention and/or treatment of disorders due to abnormal lipid metabolism, such as hypercholesterolaemia, atherosclerosis, hyperlipidaemia and obesity, and which can therefore take the form of a dietary supplement or of an actual medicine, comprising as characterising active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, and (b) chitosan or its derivatives and congeners
In the existing system as given in WO/2002 060510 wherein A palatable viscous carrier for delivery of a variety of ingestible substances including dietary supplements, therapeutic agents, vitamins, and other probiotic agents. In addition, the present invention protects components from contact with atmospheric oxygen and water that may degrade their quality. The present invention also provides a natural oil coating to protect the ingestible substances from degradation by stomach acids. Furthermore, the vehicle, herein described, is easily dispensed using inexpensive, commonly available packaging such as collapsible tubes, two compartment aerosols, and pump dispensers. The vehicle of the present invention is an anhydrous, hydrophobic, nontoxic vegetable oil base that can be made using commonly used manufacturing equipment. The invention is directed primarily to veterinary applications, but also has applications in any industry involving the delivery of nutritional supplements and probiotic agents to living creatures.
In the existing system as given in WO/2007/061753 wherein The present invention relates generally to functional sweetener compositions comprising non-caloric or low-caloric natural and/or synthetic high-potency sweeteners and methods for making and using them. In particular, the present invention relates to different functional sweetener compositions comprising at least one non-caloric or low- caloric natural and or synthetic high potency sweetener, at least one sweet taste improving composition, and at least one functional ingredient, such as glucosamine. The present invention also relates to functional sweetener compositions and methods that can improve the tastes of non-caloric or low-caloric high- potency sweeteners by imparting a more sugar-like taste or characteristic. In particular, the functional sweetener compositions and methods provide a more sugar-like temporal profile, including sweetness onset and sweetness linger, and/or a more sugar-like flavor profile.
In the existing system as given in United Slates Patent Application 20030180389 wherein A composition which acts to protect, maintain and repair connective tissue in mammals. The composition includes glucosamine, chondroitin sulfate and sulfur in an effervescent base as its major elements. The effervescent base includes one or more acids and one or more bases and may also include a starch, a flavoring agent and a coloring agent. The composition can be formed into a tablet or can be granular. The tablet or granular mixture is dissolved in a neutral pH liquid such as water for consumption purposes
In the existing system as given in WO/2005/079764 wherein The present invention relates to compositions of and methods for producing timed or retarded release formulations that contain glucosamine sulfate, beta-(l,4)-2-amino-2-deoxy-D-glucose, and chondroitin, (C14 H19 N 014 S Na2)n; N-acetylchondrosamine (2-acetamide-2-deoxi-D-galactopiranose) and D-gluoronic acid copolymer and/or their dietary and nutraceutically acceptable salts of the same and/or hydrates of the active substance that provide a timed release formulation of the active substance.
In the existing system as given in United States Patent 5736154 wherein A drug delivery system useful in treating individuals having maladies requiring topical, subcutaneous and intra-lesional administration of one or more drugs for a prolonged period of time. A method for treating individuals with noduloulcerative carcinomas using the present invention drug delivery system and intra-lesional administration of interferon to the individual in a controlled, sustained release manner such that long-term therapeutic levels of interferon are provided to the individual. A method of treating an individual having certain skin infections using the present invention drug delivery system including topical and/or subcutaneous administration of one or more drugs to the individual in a controlled, sustained release manner such that long-term therapeutic levels of the drug(s) are provided to the individual.
In the existing system as given in WO/2008/057968 wherein the present invention relates generally to anti-diabetic compositions comprising non-caloric or low-caloric high-potency sweeteners and methods for making and using mem. In particular, the present invention relates to different anti-diabetic compositions comprising at least one non-caloric or low- caloric natural and/or synthetic high-potency sweetener, at least one sweet taste improving composition, and an anti-diabetic substance. The present invention also relates to antidiabetic compositions and methods that can improve the tastes of non-caloric or low-caloric natural and/or synthetic, high-potency sweeteners by imparting a more sugar-like taste or characteristic. In particular, the anti-diabetic compositions and methods provide a more sugar-like temporal profile, including sweetness onset and sweetness linger, and or a more sugar-like flavor profile.
In the existing system as given in United States Patent 7282224 wherein Disclosed is a pain relief composition comprising an effective amount of a nerve inhibiting component, including capsaicin, a capsaicinoid or a capsaicin analogue, which numbs or inhibits the nerve endings that signal pain, in combination with at least one of the following: an effective amount of an inflammation control component which is designed to reduce immediate pain and discourage future pain in the joints and muscles; an effective amount of a cooling component; an effective amount of a heat minimizing or blocking component; an effective amount of a circulation increasing component which effectuates better penetration of the actives to the skin and nerves; and an effective amount of a soothing and anti-inflammatory complex for the joints and/or muscles comprising Glucosamine sulfate or HC1, Zingiber officiniale (Ginger Root) extract, Methyl sulfonylmethane (MSM), Polygonum cuspidatum (Mexican Bamboo) extract, Aloe barbadensis leaf, and Salix alba (white willow) bark extract. Additionally, the composition includes an encapsulation or entrapment system for a timed release delivery.
In the existing system as given in United States Patent Application 20030118672 wherein This invention provides methods and formulations for treating an inflammatory disease or reducing an inflammatory reaction comprising administering a fortified formulation comprising stabilized rice bran derivative and a fortification agent. Preferred rice bran derivatives are rice bran oil and the solubilized fraction of rice bran. Preferred fortification agents are glucosamine derivative, methylsulfonylmethane, yucca concentrate, and grape seed extract. 2 000045
In the existing system as given in AU 2001/014576 Al (patent application) wherein Provided is a synergistic combination of nutritional supplements classified as Nutraceuticals and further combined with antioxidant vitamins and minerals that, when orally administered to mammals, provides optimal delivery of vital metabolic precursors necessary for the production and repair of articular cartilage. Specifically provided is, a unique combination of chondroitin sulfate sodium, methylsulfonylmethane, glucosamine potassium, glucosamine hydrochloride, glucosamine sulfate sodium, N-acetyl D-Glucosamine, sodium absorbate and chelated manganese proteinate compounded through agitation. The provided compositions and methods of administration are designed to effectively elevate and sustain blood levels of said compounds in turn enhancing the body's natural chondroprotective mechanisms while providing an efficient delivery mechanism which optimizes cellular uptake of glucosamine and chondroitin. This process of forming specified synergistic relationships between vital metabolic precursors increases the body's production of proteoglycans, chondrocytes, hyalauron glycosaminoglycans and collagen, facilitating the repair and regeneration of articular cartilage and symptomatic relief from pain and inflammation associated with articular degeneration.
THE OBJECT OF THE 1NVENTION-
The object of the present invention is to introduce the use of an effective ingredient which is used in the treatment of arthritis. Existing treatments has allergic effects and are costly. This invention provides the novel combination of active ingredients which are Glucosamine, MSM (Methyl Suphonil Methane ), Taurine and Racemethionin.
These ingredients in Arthritis have been united to work in a specific combination and dosage to aid in reducing and eliminating the joints pain, arthritis and cartilage quality.
These combinations provides highly improved medicament which is mild, without any side effects. There are medications of arthritis which show mild side effects which are visible for example, skin rashes, while others may not be as obvious such as elevated liver enzymes. It may prevent further damage of the joints and loss of function, without causing permanent or unacceptable side effects. NSAIDs (nonsteroidal anti-inflammatory drugs), initially may cause slight stomach upset when you take the pill and is capable of causing severe problems as well.
STATEMENT OF INVENTION
An efficient pharmaceutical combination for the treatment of arthritis, it's to reduce inflammation of bones and joint friction with improve cartilage quality. The present invention provides novel and cost effective medicament of the active ingredients which are Glucosamine, MSM (Methyl Suphonil Methane ), Taurine and Racemethionin. DETAILED DESCRIPTION OF THE INVENTION
The present invention discloses novel, safe and economical composition for the joints pain treatments which comprises of the combination of four active ingredients like Glucosamine, MSM (Methyl Suphonil Methane), Taurine and Racemethionin. The present invention is used for the treatment of arthritis, joints pain and improves cartilage quality also.
Arthritis can cause enormous pain and loss of movement. There are several kinds of arthritis. The two most common types are rheumatoid arthritis and osteoarthritis.
Perceptibly reduce inflammation, swelling and stiffness, Achieve long term pain relief by targeting the cause not just the symptoms, Protect and even restore affected joints.
This invention comprises of following effective ingredients.
Glucosamine- Glucosamine is found in high concentrations in the joints. It has been theorized that glucosamine stimulates the formation of cartilage that is essential for joint repair. It has a beneficial effect on inflammation, mechanical arthritis, and immunological-reactive arthritis. It is natural. Glucosamine builds and maintains cartilage, tendons and other connective tissues in the body by acting as a building block for these materials and inhibiting enzymes that destroy cartilage. Glucosamine works by preventing the cartilage destruction, joint pain, swelling and loss of flexibility in a natural way and without the harmful side effects. It's the most popular arthritis nutrients, it's naturally occurring compounds that can aid in joint health and repair.The concentration of Glucosamine is 500mg/ capsule.
MSM
Methyl sulfonyl methane or MSM is a naturally occurring sulfur containing molecule found in fruits, vegetables, seafood and meat
It's commonly used for helping to treat or prevent osteoarthritis. MSM has anti-inflammatory effects. MSM significantly reduce pain and improve physical functioning, without major adverse events. Enhances permeability of cell membranes and reduces inflammation.
MSM aids in detoxifying metals by contributing sulfur to methionine and cysteine as well as peptides and proteins and is eventually incorporated into connective tissue. It's a naturally occurring sulfur compound that acts as an anti-inflammatory; MSM can reduce swelling much like other arthritis medications.
The concentration of Methyl sulfonyl methane is 25 mg /capsule. Taurine
It's popular as a supplemental ingredient Taurine tends to be well absorbed and tissue levels can go up rapidly after oral administration. Most of the supplemental uses of taurine is related to cardiovascular or muscle conditions. It does provide energy. The concentration of Taurine is 500 mg capsule.
Racemethionin
L-Methionine has antioxidant properties. Methionine is one of the three amino acids needed by the body to manufacture Creation, an amino acid essential for energy production and muscle building. The concentration of racemethionin is 100 mg/capsule

Claims

CLAIMS,
1. An exclusive formulation to reduce inflammation bones and joint friction with improve cartilage quality.
2. An exclusive formulation comprises of Glucosamine, MSM (Methyl Suphonil Methane) , Taurine and Racemethionin.
3. An exclusive formulation in claimed 2, wherein the concentration of Glucosamine is 500mg/ capsule.
4. An exclusive formulation in claimed 2, wherein the concentration of Methyl sulfonyl methane is 25 mg /capsule.
5. An exclusive formulation in claimed 2, wherein the concentration of Taurine is 500 mg/capsule.
6. An exclusive formulation in claimed 2, wherein the concentration of racemethionin is 100 mg capsule.
PCT/IN2012/000045 2012-01-18 2012-01-18 Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality WO2013108263A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2012/000045 WO2013108263A1 (en) 2012-01-18 2012-01-18 Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2012/000045 WO2013108263A1 (en) 2012-01-18 2012-01-18 Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality

Publications (1)

Publication Number Publication Date
WO2013108263A1 true WO2013108263A1 (en) 2013-07-25

Family

ID=45888451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000045 WO2013108263A1 (en) 2012-01-18 2012-01-18 Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality

Country Status (1)

Country Link
WO (1) WO2013108263A1 (en)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0826982A (en) * 1994-07-15 1996-01-30 Lion Corp Preventing and therapeutic agent for osteoporosis
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
ZA995557B (en) * 1998-05-29 2000-04-12 Log Negentien Beleggings Pty L A chemical substance.
WO2002060510A2 (en) 2000-12-22 2002-08-08 Global Access, Inc. Medium and method for delivery of edible materials subject to degradation by oxidation and hydrolysis
US20030118672A1 (en) 2001-07-23 2003-06-26 Nutrastar Methods for treating joint inflammation, pain, and loss of mobility
US20030180389A1 (en) 1999-08-25 2003-09-25 Phillips Cleve Alan Effervescent glucosamine, chondroitin and MSM formula
US6780851B1 (en) 1999-11-18 2004-08-24 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl l-carnitine and chitosan
US20050053674A1 (en) 2003-09-05 2005-03-10 Aleksandra Niedzwiecki Pharmaceutical composition and method for retardation of the progression of atherosclerosis
WO2005041999A1 (en) 2003-10-21 2005-05-12 Motion Potion, Inc. Composition to enhance joint function and repair
WO2005079764A1 (en) 2004-02-18 2005-09-01 Osmopharm Usa Compositions and methods for timed release of water-soluble nutritional supplements
WO2007061753A2 (en) 2005-11-23 2007-05-31 The Coca-Cola Company High-potency sweetener composition with glucosamine and compositions sweetened therewith
US7282224B1 (en) 2006-06-09 2007-10-16 Guthy-Renker Corporation Pain relief composition
WO2008057968A2 (en) 2006-11-02 2008-05-15 The Coca-Cola Company Anti-diabetic composition with high-potency sweetener
US20090258947A1 (en) 2006-04-24 2009-10-15 Rajesh Jain Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0826982A (en) * 1994-07-15 1996-01-30 Lion Corp Preventing and therapeutic agent for osteoporosis
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
ZA995557B (en) * 1998-05-29 2000-04-12 Log Negentien Beleggings Pty L A chemical substance.
US20030180389A1 (en) 1999-08-25 2003-09-25 Phillips Cleve Alan Effervescent glucosamine, chondroitin and MSM formula
US6780851B1 (en) 1999-11-18 2004-08-24 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl l-carnitine and chitosan
WO2002060510A2 (en) 2000-12-22 2002-08-08 Global Access, Inc. Medium and method for delivery of edible materials subject to degradation by oxidation and hydrolysis
US20030118672A1 (en) 2001-07-23 2003-06-26 Nutrastar Methods for treating joint inflammation, pain, and loss of mobility
US20050053674A1 (en) 2003-09-05 2005-03-10 Aleksandra Niedzwiecki Pharmaceutical composition and method for retardation of the progression of atherosclerosis
US20070166400A1 (en) 2003-09-05 2007-07-19 Matthias Rath Pharmaceutical composition comprising i.a. vitamin c, magnesium green tea extract for retarding cardiovascular disease
WO2005041999A1 (en) 2003-10-21 2005-05-12 Motion Potion, Inc. Composition to enhance joint function and repair
WO2005079764A1 (en) 2004-02-18 2005-09-01 Osmopharm Usa Compositions and methods for timed release of water-soluble nutritional supplements
WO2007061753A2 (en) 2005-11-23 2007-05-31 The Coca-Cola Company High-potency sweetener composition with glucosamine and compositions sweetened therewith
US20090258947A1 (en) 2006-04-24 2009-10-15 Rajesh Jain Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
US7282224B1 (en) 2006-06-09 2007-10-16 Guthy-Renker Corporation Pain relief composition
WO2008057968A2 (en) 2006-11-02 2008-05-15 The Coca-Cola Company Anti-diabetic composition with high-potency sweetener

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199614, Derwent World Patents Index; AN 1996-136174, XP002674550 *
DELRIEU F ET AL: "[Preliminary study of L-methionine in the treatment of rheumatoid polyarthritis]", REVUE DU RHUMATISME ET DES MALADIES OSTÉO-ARTICULAIRES, EXPANSION SCIENTIFIQUE FRANCAISE, PARIS, FR, vol. 55, no. 2, 1 December 1988 (1988-12-01), pages 995 - 997, XP009158725, ISSN: 0035-2659 *

Similar Documents

Publication Publication Date Title
US5840715A (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
DE102008036954B4 (en) Use of an amino sugar-containing composition
US6136795A (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US20050282772A1 (en) New dietary supplement composition for obesity and inflammation
US9408894B2 (en) Anti-fatigue composition
WO2013132668A1 (en) Composition comprising imidazole peptide and quercetin glycoside
EP0855908B1 (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US20080031869A1 (en) Pain relief composition
CA2731282C (en) Anti-fatigue composition
US20030125303A1 (en) Transdermal formulation for repair and maintenance of connective tissue
KR20110117685A (en) A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
US20050113287A1 (en) Composition to enhance joint function and repair
JP2007099653A (en) Arthrodynia ameliorator
RU2468812C2 (en) Agent possessing adaptogenic, tonic and general tonic action, and method for preparing it
Klatz The Official Anti-Aging Revolution: Stop the Clock Time is on Your Side for a Younger, Stronger, Happier You
US20150328176A1 (en) Composition for treatment of neurodegenerative disease
JP4143387B2 (en) healthy food
WO2013108263A1 (en) Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality
JP2006166807A (en) Health and beauty food
SG188424A1 (en) Ingredients derived from sphaeranthus indicus
JP6840647B2 (en) Liquid composition, its cloudiness improving agent, odor improving agent, and manufacturing method
KR20110011233A (en) Composition for reducing fatigue containing chito-oligosaccharide
JP6736251B2 (en) Oral composition
WO2002028400A1 (en) A therapeutic formulation containing glucosamine, methylsulfonymethane and eventually ascorbic acid and manganese
JP5854578B2 (en) Muscle enhancer or basal metabolism enhancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12710799

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12710799

Country of ref document: EP

Kind code of ref document: A1